TABLE 2.

Assessment of drug impact on rat serum calcium and creatinine concentrations

Assay	Day	Mean concn in serum ± SDa
		Control	AMB	ABLC	EDTA	ABLC + EDTA
Calciumb	0 (baseline)	11.0 ± 0.50	10.7 ± 0.47	10.7 ± 0.38	10.8 ± 0.26	11.1 ± 0.31
	7	10.9 ± 0.55	10.8 ± 0.38	10.4 ± 0.70	10.6 ± 0.40	10.8 ± 0.44
	20	10.0 ± 0.72	9.0 ± 0.57	9.3 ± 0.76	9.4 ± 0.67	9.9 ± 0.40
Creatininec	0 (baseline)	0.63 ± 0.058	0.57 ± 0.058	0.57 ± 0.115	0.53 ± 0.058	0.60 ± 0.100
	7	0.57 ± 0.058	0.60 ± 0.100	0.57 ± 0.058	0.53 ± 0.058	0.53 ± 0.058
	20	0.63 ± 0.058	0.57 ± 0.058	0.57 ± 0.058	0.70 ± 0.100	0.57 ± 0.058

^aChanges in serum calcium and creatinine concentration were detected in nine rats from each group using analysis of variance tests.

^bCalcium concentrations in the AMB group decreased by 15% from baseline to day 20 and by 16% from day 7 to day 20; in the EDTA group, it decreased by 13% from baseline to day 20 and by 11% from day 7 to day 20; and in the combination group ABLC plus EDTA, it decreased by 10% from baseline to day 20.

^cThere was no significant change in creatinine concentration for any group during the study.